Cite

HARVARD Citation

    Guo, B. et al. (2019). A Utility-Based Bayesian Phase I–II Design for Immunotherapy Trials with Progression-Free Survival End Point. Journal of the Royal Statistical Society. 68 (2), pp. 411-425. [Online]. 
  
Back to record